The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

Table 3 Comparison of age, duration of disease, final dose, frequency of administration of canakinumab and number of adjustments (dose and/or frequency) performed during 12 months in patients with MWS and CINCA

	Muckle-Wells (6 patients)¹	CINCA (7 patients)	P-value²
Age, years, median (range)	13.6 (10.7, 23.7)	15 (8.7, 38.0)	0.56*
Disease duration, median, years (range)	13,6 (3.0, 23.2)	15 (8.7, 38.0)	0.61*
Dose, mg/kg, median (range)	2.15 (2.0, 3.7)	3.7 (2.0, 5.9)	0.16*
Frequency, weeks, median (range)	8 (6, 10)	6 (4, 8)	0.03
Adjustments/year, number	2	9	0.05

¹Includes two patients with a Muckle-Wells syndrome (MWS)/chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; ²Mann-Whitney U-test, *not significant.

ISSN: 1478-6362